Literature DB >> 7697080

After treatment ends: neutral time.

G J Hurt, R P McQuellon, R J Barrett.   

Abstract

For persons diagnosed with cancer, the remission period may be marked by increased anxiety and distress. While the medical team may view remission as an eagerly anticipated milestone, the decreased medical surveillance during this time can cause a heightened fear of recurrence for the patient. One author has called this period of remission "neutral time," a time characterized by uncertainty. The safety signal hypothesis, developed by Martin Seligman, may help to explain the anxiety experienced by some patients during the remission period. Because cancer is frequently a silent disease with no overt symptoms, patients in remission often have no safety signal to indicate that the disease will not return. A case study is presented and discussed in light of these two concepts.

Entities:  

Mesh:

Year:  1994        PMID: 7697080

Source DB:  PubMed          Journal:  Cancer Pract        ISSN: 1065-4704


  4 in total

1.  Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors.

Authors:  Qiuling Shi; Tenbroeck G Smith; Jared D Michonski; Kevin D Stein; Chiewkwei Kaw; Charles S Cleeland
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

2.  Factors associated with psychological distress among women of African descent at high risk for BRCA mutations.

Authors:  Yael R Cukier; Hayley S Thompson; Katarina Sussner; Andrea Forman; Lina Jandorf; Tiffany Edwards; Dana H Bovbjerg; Marc D Schwartz; Heiddis B Valdimarsdottir
Journal:  J Genet Couns       Date:  2012-06-27       Impact factor: 2.537

3.  An evaluation of the quality of life among long-term survivors of breast cancer.

Authors:  K H Dow; B R Ferrell; S Leigh; J Ly; P Gulasekaram
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Acute stress trajectories 1 year after a breast cancer diagnosis.

Authors:  Sandra Pérez; Andrea Conchado; Yolanda Andreu; María José Galdón; Etzel Cardeña; Elena Ibáñez; Estrella Durá
Journal:  Support Care Cancer       Date:  2015-09-28       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.